300119 瑞普生物
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,099,03810.56%2,248,9622,084,2502,007,1382,000,407
减:营业总成本930,26512.91%1,874,3331,731,9311,651,9791,596,400
    其中:营业成本565,79418.52%1,131,5121,074,613967,366919,394
               财务费用10,34911.38%18,94017,34718,78425,556
               资产减值损失382-50.51%580473(853)(818)
公允价值变动收益14,892-32.19%61,26051,383113,796116,745
投资收益1,644-92.32%15,1514,05118,4661,512
    其中:对联营企业和合营企业的投资收益1,518-92.88%21,3558284,4841,138
营业利润189,080-12.42%565,230416,638499,360513,120
利润总额188,310-12.46%566,680413,811487,787510,917
减:所得税费用20,502-5.23%55,66340,04254,19871,426
净利润167,809-13.27%511,017373,770433,590439,491
减:非控股权益8,669-42.98%58,07527,07120,80541,294
股东净利润159,139-10.73%452,942346,699412,785398,197

市场价值指针
每股收益 (元) *0.346-10.07%0.9770.7491.0261.006
每股派息 (元) *----0.4000.3000.3500.400
每股净资产 (元) *9.5735.08%9.6439.0206.6296.071
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容